In my commitment to report “On the Horizon” treatments for advanced prostate cancer today I will discuss an investigational treatment known as Tasquinimod. It is an experimental treatment that is both an immunotherapy and anti-angiogenic agent (designed to prevent the development of blood vesicles which would feed a tumor allowing its growth). In phase 2 [...]
Research performed at the University of Queensland has shown that a diet, which is high in cholesterol, might increase the spread of prostate cancer tumors to lymph nodes, lungs and bones. According to the UQ Diamantina Institute study leader Dr Michelle Hill this research highlighted why it is important for men with prostate cancer to [...]
Despite its approval five years ago sipuleucel-T (Provenge) remains one of the most controversial treatments available for men with castrate resistant metastatic prostate cancer (mCRPC). Provenge has its advocates (Full Disclosure- I am) and it has many detractors. The detractors argue that it doesn’t work and they hang their hat on the argument that it [...]
The only thing more powerful than a story, is a decision. Help men find their way through prostate cancer treatment choices by telling your story here on Twice As Many.
Our Twice As Many logo is now in beta. The red "w" and "m" visualize the idea of "twice," where each letter presents two repeating elements. The color red signifies, "cancer," much like it does for Malecare's primary logo. We have incorporated Malecare's logo in the Twice As Many logo to highlight the unity of [...]